A big percentage of the very recent investors probably are unaware that MK gives a monthly summary. It is crazy to bail when that update is less than a week away and the list of items he could address in his update include the following (these are listed in order of potential impact to share price)
- FDA's response to the preliminary data points from the rabbit study that was planned to be shared with the FDA in April. - results of meeting with FDA to discuss their last draft IDE submitted in Feb that contains all sections except the results of the rabbit study - outcome of Mayo doctors surrogate injection training that was planned for April - preliminary results of analysis of data and histopathology specimens - progress of Phase 2 testing (final testing not for safety or efficacy but to determine ideal dose)
RDGL is brewing with potential and we are guaranteed to learn something about progress at the end of this month (if not sooner via the PR the company mentioned could come out before then).
News 
Market Data 
Discover 
